We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) updated its pharmaceutical marketing practice code, creating tougher restrictions on the gifts healthcare professionals can receive, the organization announced.
The FDA approved only two new drug applications (NDAs) in November, but the approval rate is up overall compared with this time in 2005, according to a report from Friedman Billings Ramsey (FBR).
Two drugs used to treat Parkinson’s disease may increase the risk for heart valve damage, according to two studies published in the New England Journal of Medicine (NEJM).
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) updated its pharmaceutical marketing practice code, creating tougher restrictions on the gifts healthcare professionals can receive, the organization announced.
The FDA is pledging to continue fighting an effort by wholesalers to stop the agency from implementing its drug-tracking rule, despite early setbacks in court.
Boston Scientific and Johnson & Johnson (J&J) face doubts about the long-term safety and market viability of their drug-eluting stents after a slew of European study findings.
As 2006 drew to a close, analysts agreed that drug-eluting stent manufacturers face a growing threat to their $5 billion-per-year market after a spate of clinical trial results pointed to an increased risk of clotting, or thrombosis, in patients implanted with the devices.